Fertility preservation and preimplantation genetic assessment for women with breast cancer
Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable f...
Ausführliche Beschreibung
Autor*in: |
Sciorio, Romualdo [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020transfer abstract |
---|
Schlagwörter: |
---|
Umfang: |
8 |
---|
Übergeordnetes Werk: |
Enthalten in: Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications - Strong, J.W.D. ELSEVIER, 2022, international journal of low temperature biology and medicine, Orlando, Fla |
---|---|
Übergeordnetes Werk: |
volume:92 ; year:2020 ; day:1 ; month:02 ; pages:1-8 ; extent:8 |
Links: |
---|
DOI / URN: |
10.1016/j.cryobiol.2019.12.001 |
---|
Katalog-ID: |
ELV050096656 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV050096656 | ||
003 | DE-627 | ||
005 | 20230626025813.0 | ||
007 | cr uuu---uuuuu | ||
008 | 200518s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.cryobiol.2019.12.001 |2 doi | |
028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001487.pica |
035 | |a (DE-627)ELV050096656 | ||
035 | |a (ELSEVIER)S0011-2240(19)30535-8 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 550 |q VZ |
084 | |a 38.00 |2 bkl | ||
100 | 1 | |a Sciorio, Romualdo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Fertility preservation and preimplantation genetic assessment for women with breast cancer |
264 | 1 | |c 2020transfer abstract | |
300 | |a 8 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. | ||
520 | |a Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. | ||
650 | 7 | |a Embryo cryopreservation |2 Elsevier | |
650 | 7 | |a Ovarian tissue cryopreservation |2 Elsevier | |
650 | 7 | |a Ovarian stimulation |2 Elsevier | |
650 | 7 | |a Fertility preservation |2 Elsevier | |
650 | 7 | |a PGT-M |2 Elsevier | |
650 | 7 | |a Oocyte cryopreservation |2 Elsevier | |
650 | 7 | |a Breast cancer |2 Elsevier | |
700 | 1 | |a Anderson, Richard A. |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Academic Press |a Strong, J.W.D. ELSEVIER |t Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |d 2022 |d international journal of low temperature biology and medicine |g Orlando, Fla |w (DE-627)ELV008369550 |
773 | 1 | 8 | |g volume:92 |g year:2020 |g day:1 |g month:02 |g pages:1-8 |g extent:8 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.cryobiol.2019.12.001 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OPC-GGO | ||
936 | b | k | |a 38.00 |j Geowissenschaften: Allgemeines |q VZ |
951 | |a AR | ||
952 | |d 92 |j 2020 |b 1 |c 0201 |h 1-8 |g 8 |
author_variant |
r s rs |
---|---|
matchkey_str |
sciorioromualdoandersonricharda:2020----:etltpeevtoadripattogntcsesetow |
hierarchy_sort_str |
2020transfer abstract |
bklnumber |
38.00 |
publishDate |
2020 |
allfields |
10.1016/j.cryobiol.2019.12.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001487.pica (DE-627)ELV050096656 (ELSEVIER)S0011-2240(19)30535-8 DE-627 ger DE-627 rakwb eng 550 VZ 38.00 bkl Sciorio, Romualdo verfasserin aut Fertility preservation and preimplantation genetic assessment for women with breast cancer 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer Elsevier Anderson, Richard A. oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:92 year:2020 day:1 month:02 pages:1-8 extent:8 https://doi.org/10.1016/j.cryobiol.2019.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 92 2020 1 0201 1-8 8 |
spelling |
10.1016/j.cryobiol.2019.12.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001487.pica (DE-627)ELV050096656 (ELSEVIER)S0011-2240(19)30535-8 DE-627 ger DE-627 rakwb eng 550 VZ 38.00 bkl Sciorio, Romualdo verfasserin aut Fertility preservation and preimplantation genetic assessment for women with breast cancer 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer Elsevier Anderson, Richard A. oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:92 year:2020 day:1 month:02 pages:1-8 extent:8 https://doi.org/10.1016/j.cryobiol.2019.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 92 2020 1 0201 1-8 8 |
allfields_unstemmed |
10.1016/j.cryobiol.2019.12.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001487.pica (DE-627)ELV050096656 (ELSEVIER)S0011-2240(19)30535-8 DE-627 ger DE-627 rakwb eng 550 VZ 38.00 bkl Sciorio, Romualdo verfasserin aut Fertility preservation and preimplantation genetic assessment for women with breast cancer 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer Elsevier Anderson, Richard A. oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:92 year:2020 day:1 month:02 pages:1-8 extent:8 https://doi.org/10.1016/j.cryobiol.2019.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 92 2020 1 0201 1-8 8 |
allfieldsGer |
10.1016/j.cryobiol.2019.12.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001487.pica (DE-627)ELV050096656 (ELSEVIER)S0011-2240(19)30535-8 DE-627 ger DE-627 rakwb eng 550 VZ 38.00 bkl Sciorio, Romualdo verfasserin aut Fertility preservation and preimplantation genetic assessment for women with breast cancer 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer Elsevier Anderson, Richard A. oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:92 year:2020 day:1 month:02 pages:1-8 extent:8 https://doi.org/10.1016/j.cryobiol.2019.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 92 2020 1 0201 1-8 8 |
allfieldsSound |
10.1016/j.cryobiol.2019.12.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001487.pica (DE-627)ELV050096656 (ELSEVIER)S0011-2240(19)30535-8 DE-627 ger DE-627 rakwb eng 550 VZ 38.00 bkl Sciorio, Romualdo verfasserin aut Fertility preservation and preimplantation genetic assessment for women with breast cancer 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer Elsevier Anderson, Richard A. oth Enthalten in Academic Press Strong, J.W.D. ELSEVIER Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications 2022 international journal of low temperature biology and medicine Orlando, Fla (DE-627)ELV008369550 volume:92 year:2020 day:1 month:02 pages:1-8 extent:8 https://doi.org/10.1016/j.cryobiol.2019.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO 38.00 Geowissenschaften: Allgemeines VZ AR 92 2020 1 0201 1-8 8 |
language |
English |
source |
Enthalten in Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications Orlando, Fla volume:92 year:2020 day:1 month:02 pages:1-8 extent:8 |
sourceStr |
Enthalten in Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications Orlando, Fla volume:92 year:2020 day:1 month:02 pages:1-8 extent:8 |
format_phy_str_mv |
Article |
bklname |
Geowissenschaften: Allgemeines |
institution |
findex.gbv.de |
topic_facet |
Embryo cryopreservation Ovarian tissue cryopreservation Ovarian stimulation Fertility preservation PGT-M Oocyte cryopreservation Breast cancer |
dewey-raw |
550 |
isfreeaccess_bool |
false |
container_title |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
authorswithroles_txt_mv |
Sciorio, Romualdo @@aut@@ Anderson, Richard A. @@oth@@ |
publishDateDaySort_date |
2020-01-01T00:00:00Z |
hierarchy_top_id |
ELV008369550 |
dewey-sort |
3550 |
id |
ELV050096656 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050096656</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626025813.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cryobiol.2019.12.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001487.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050096656</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0011-2240(19)30535-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">550</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">38.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sciorio, Romualdo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fertility preservation and preimplantation genetic assessment for women with breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Embryo cryopreservation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ovarian tissue cryopreservation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ovarian stimulation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fertility preservation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PGT-M</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oocyte cryopreservation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anderson, Richard A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Strong, J.W.D. ELSEVIER</subfield><subfield code="t">Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications</subfield><subfield code="d">2022</subfield><subfield code="d">international journal of low temperature biology and medicine</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV008369550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:92</subfield><subfield code="g">year:2020</subfield><subfield code="g">day:1</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:1-8</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cryobiol.2019.12.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">38.00</subfield><subfield code="j">Geowissenschaften: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">92</subfield><subfield code="j">2020</subfield><subfield code="b">1</subfield><subfield code="c">0201</subfield><subfield code="h">1-8</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
author |
Sciorio, Romualdo |
spellingShingle |
Sciorio, Romualdo ddc 550 bkl 38.00 Elsevier Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer Fertility preservation and preimplantation genetic assessment for women with breast cancer |
authorStr |
Sciorio, Romualdo |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008369550 |
format |
electronic Article |
dewey-ones |
550 - Earth sciences |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
550 VZ 38.00 bkl Fertility preservation and preimplantation genetic assessment for women with breast cancer Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer Elsevier |
topic |
ddc 550 bkl 38.00 Elsevier Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer |
topic_unstemmed |
ddc 550 bkl 38.00 Elsevier Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer |
topic_browse |
ddc 550 bkl 38.00 Elsevier Embryo cryopreservation Elsevier Ovarian tissue cryopreservation Elsevier Ovarian stimulation Elsevier Fertility preservation Elsevier PGT-M Elsevier Oocyte cryopreservation Elsevier Breast cancer |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
r a a ra raa |
hierarchy_parent_title |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
hierarchy_parent_id |
ELV008369550 |
dewey-tens |
550 - Earth sciences & geology |
hierarchy_top_title |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV008369550 |
title |
Fertility preservation and preimplantation genetic assessment for women with breast cancer |
ctrlnum |
(DE-627)ELV050096656 (ELSEVIER)S0011-2240(19)30535-8 |
title_full |
Fertility preservation and preimplantation genetic assessment for women with breast cancer |
author_sort |
Sciorio, Romualdo |
journal |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
journalStr |
Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
500 - Science |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
zzz |
container_start_page |
1 |
author_browse |
Sciorio, Romualdo |
container_volume |
92 |
physical |
8 |
class |
550 VZ 38.00 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Sciorio, Romualdo |
doi_str_mv |
10.1016/j.cryobiol.2019.12.001 |
dewey-full |
550 |
title_sort |
fertility preservation and preimplantation genetic assessment for women with breast cancer |
title_auth |
Fertility preservation and preimplantation genetic assessment for women with breast cancer |
abstract |
Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. |
abstractGer |
Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. |
abstract_unstemmed |
Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GGO |
title_short |
Fertility preservation and preimplantation genetic assessment for women with breast cancer |
url |
https://doi.org/10.1016/j.cryobiol.2019.12.001 |
remote_bool |
true |
author2 |
Anderson, Richard A. |
author2Str |
Anderson, Richard A. |
ppnlink |
ELV008369550 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth |
doi_str |
10.1016/j.cryobiol.2019.12.001 |
up_date |
2024-07-06T16:36:05.995Z |
_version_ |
1803848270213021696 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050096656</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626025813.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cryobiol.2019.12.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001487.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050096656</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0011-2240(19)30535-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">550</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">38.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sciorio, Romualdo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fertility preservation and preimplantation genetic assessment for women with breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Embryo cryopreservation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ovarian tissue cryopreservation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ovarian stimulation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fertility preservation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PGT-M</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oocyte cryopreservation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anderson, Richard A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Strong, J.W.D. ELSEVIER</subfield><subfield code="t">Eo-Paleoarchean detrital zircon in the Winnipeg River terrane, Western Superior Province: Provenance and implications</subfield><subfield code="d">2022</subfield><subfield code="d">international journal of low temperature biology and medicine</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV008369550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:92</subfield><subfield code="g">year:2020</subfield><subfield code="g">day:1</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:1-8</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cryobiol.2019.12.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">38.00</subfield><subfield code="j">Geowissenschaften: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">92</subfield><subfield code="j">2020</subfield><subfield code="b">1</subfield><subfield code="c">0201</subfield><subfield code="h">1-8</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
score |
7.4002275 |